Panel: Oncology Business Models Determined By Capital And Culture
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.
You may also be interested in...
Astex Aims To Make Cancer Drug Resistance Futile
“Using our drugs, we’re trying to facilitate the old drugs or help them work better longer,” Astex’s Lyons said. Astex, AstraZeneca and Novartis all presented data on compounds from Astex’s fragment-based drug discovery platform at the recent American Association for Cancer Research meeting in Washington, D.C.
Exelixis Explains Virtues Of Flat Pricing For Cometriq
Approval in very rare medullary thyroid cancer marks an important milestone for Exelixis’ Cometriq (cabozantinib), which is being positioned for multiple cancers. The company will need only five sales reps for the thyroid cancer market and plans to launch in late January 2013 at the price of $9,900 per 28 days.
Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.